Childhood absence epilepsy — RACP Paediatrics MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: B — Ethosuximide
Ethosuximide is the first-line treatment for childhood absence epilepsy per multiple guidelines. The SANAD trial demonstrated it is as effective as valproate for absence seizures with fewer side effects. Sodium valproate is an alternative, particularly if generalised tonic-clonic seizures also occur.
Reference: Australian Therapeutic Guidelines – 2024 – Neurology; RACP Paediatric Curriculum – Neurology